Market Overview:
The global lenalidomide drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of multiple myeloma (MM) and myelodysplastic syndromes (MDS), rising demand for novel therapies, and growing investments by pharmaceutical companies in R&D. Based on type, the global lenalidomide drug market can be segmented into 5 mg capsules, 10 mg capsules, 15 mg capsules, and 25 mg capsules. The 5 mg capsule segment is expected to account for the largest share of the global lenalidomide drug market in 2018. This segment is also projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. Based on application, the global lenalidomide drug market can be divided into multiple myeloma (MM), myelodysplastic syndromes (MDS), and other applications. The MM segment is expected to account for the largest share of the global lenalidomide drug market in 2018.
Product Definition:
Lenalidomide is a drug used to treat multiple myeloma, a type of blood cancer. It is also being studied for use in other cancers.
5 mg Capsules:
5 mg capsules are used for the treatment of multiple myeloma and lymphomas. It works by reducing the production of cytokines which causes an immune response in patients. The drug is manufactured by a number of companies including Bayer Healthcare, Mylan Pharmaceuticals Ltd., and Wockhardt Limited.
10 mg Capsules:
10 mg capsules are used for the treatment of multiple myeloma and lymphomas. It is also used as a part of combination therapy with other drugs to treat these diseases. The drug is manufactured by Novartis AG, which is a Swiss company.
Application Insights:
The multiple myeloma segment dominated the global lenalidomide market in terms of revenue share in 2017. Increasing awareness about MM and availability of effective treatment options are the major factors driving the segment growth. Moreover, increasing research & development activities by various players to introduce new products with better efficacy and fewer side effects will further boost market growth over the forecast period.
Myelodysplastic syndromes (MDS) is expected to be one of the fastest-growing application segments during the forecast period due to rising incidence rates of MDS across various regions including North America, Europe, Asia Pacific and Middle East & Africa. In addition, presence of key players engaged in R&D for developing novel drugs for treating MDS will further propel market growth over next eight years.
Other applications include osteosarcoma as well as other blood disorders such as acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).
Regional Analysis:
Europe dominated the global lenalidomide market in 2017, with a revenue share of over 35.0%. Key factors responsible for its large share include lenalidomide’s approval in the European Union (EU) and increasing number of patients diagnosed with blood disorders such as MDS and MM. Moreover, lenalidomide is approved for use in more than 15 countries across Europe making it one of the most widely prescribed drugs across this region.
The Asia Pacific is expected to be the fastest-growing regional market during forecast years owing to an increase in awareness about various treatment options along with rising healthcare expenditure levels & improving healthcare infrastructure especially in Japan & China. In addition, emerging markets such as India are also estimated to witness lucrative growth over the coming years due to growing target disease population along with increased investment by pharmaceutical companies for new product development initiatives aimed at treating blood disorders including MDS and MM.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the lenalidomide drug market. According to a study by the World Health Organization (WHO), it is estimated that there will be around 18 million new cases of cancer and 9.6 million deaths due to cancer in 2018. This number is expected to rise significantly in the coming years, thereby driving demand for lenalidomide drugs.
- Rising prevalence of multiple myeloma: The rising prevalence of multiple myeloma is another key growth driver for the lenalidomide drug market. Multiple myeloma is a type of blood cancer that affects plasma cells in bone marrow and leads to excessive production of abnormal antibodies called M proteins. This condition often requires treatment with lenalidomide drugs, which helps control tumor growth and improve patient prognosis considerably.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lenalidomide Drug Market Research Report
By Type
5 mg Capsules, 10 mg Capsules, 15 mg Capsules, 25 mg Capsules
By Application
Multiple myeloma (MM), Myelodysplastic syndromes (MDS), Other
By Companies
Celgene, Exova, Celgene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
199
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Lenalidomide Drug Market Report Segments:
The global Lenalidomide Drug market is segmented on the basis of:
Types
5 mg Capsules, 10 mg Capsules, 15 mg Capsules, 25 mg Capsules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Multiple myeloma (MM), Myelodysplastic syndromes (MDS), Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Exova
- Celgene
Highlights of The Lenalidomide Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 5 mg Capsules
- 10 mg Capsules
- 15 mg Capsules
- 25 mg Capsules
- By Application:
- Multiple myeloma (MM)
- Myelodysplastic syndromes (MDS)
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lenalidomide Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lenalidomide is a chemotherapy drug used to treat multiple myeloma. It works by stopping the growth of cancer cells.
Some of the major companies in the lenalidomide drug market are Celgene, Exova, Celgene.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lenalidomide Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lenalidomide Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lenalidomide Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lenalidomide Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lenalidomide Drug Market Size & Forecast, 2020-2028
4.5.1 Lenalidomide Drug Market Size and Y-o-Y Growth
4.5.2 Lenalidomide Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 5 mg Capsules
5.2.2 10 mg Capsules
5.2.3 15 mg Capsules
5.2.4 25 mg Capsules
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Multiple myeloma (MM)
6.2.2 Myelodysplastic syndromes (MDS)
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lenalidomide Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lenalidomide Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 5 mg Capsules
9.6.2 10 mg Capsules
9.6.3 15 mg Capsules
9.6.4 25 mg Capsules
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Multiple myeloma (MM)
9.10.2 Myelodysplastic syndromes (MDS)
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 5 mg Capsules
10.6.2 10 mg Capsules
10.6.3 15 mg Capsules
10.6.4 25 mg Capsules
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Multiple myeloma (MM)
10.10.2 Myelodysplastic syndromes (MDS)
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 5 mg Capsules
11.6.2 10 mg Capsules
11.6.3 15 mg Capsules
11.6.4 25 mg Capsules
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Multiple myeloma (MM)
11.10.2 Myelodysplastic syndromes (MDS)
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 5 mg Capsules
12.6.2 10 mg Capsules
12.6.3 15 mg Capsules
12.6.4 25 mg Capsules
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Multiple myeloma (MM)
12.10.2 Myelodysplastic syndromes (MDS)
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 5 mg Capsules
13.6.2 10 mg Capsules
13.6.3 15 mg Capsules
13.6.4 25 mg Capsules
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Multiple myeloma (MM)
13.10.2 Myelodysplastic syndromes (MDS)
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lenalidomide Drug Market: Competitive Dashboard
14.2 Global Lenalidomide Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
14.3.2 Exova
14.3.3 Celgene
